A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants.

Citation metadata

From: The New England Journal of Medicine(Vol. 382, Issue 3)
Publisher: Massachusetts Medical Society
Document Type: Report
Length: 49 words

Document controls

Main content

Abstract :

High-dose erythropoietin treatments were administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age. In 376 who received erythropoietin and 365 who received placebo, there was no significant difference in the incidence of death or severe neurodevelopmental impairment at 2 years of age.

Source Citation

Source Citation   

Gale Document Number: GALE|A629580769